Prognosis and Survival Analysis of 922,317 Lung Cancer Patients from the US Based on the Most Recent Data from the SEER Database (April 15, 2021)

Sheng, Hu; Zhang, Wen‐Xiong; Guo, Qiang; Ye, Jiayue; Zhang, Deyuan; Zhang, Yang; Zeng, Weibiao; Yu, Dongliang; Peng, Jinhua; Wei, Yiping; Xu, Jianjun

doi:10.2147/ijgm.s338250

Cited by 16 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They discovered a 41.72% increase in the median survival time of all lung cancer patients. Adenocarcinoma patients had a 5% increase in median survival compared with a 3% increase in squamous patients [ 12 ] OS of American population statistics in adenocarcinoma and squamous cell carcinoma was consistent with our study, with a 2.71% increase in the SEER database. We revealed no significant differences in the overall survival curve of squamous patients.…”

Section: Discussionsupporting

confidence: 89%

Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

Tsai

Huang

Hsieh

et al. 2022

JCM

View full text Add to dashboard Cite

Objective: Lung cancer poses a tremendous threat to the modern world. According to Taiwan’s Ministry of Health and Welfare, lung cancer took first place in total cancer deaths in 2021. This study investigated the overall lung cancer survival based on histopathology between 2010 and 2016 in Taiwan. Method: Data from 2010 to 2016 was collected from the Taiwan Cancer Registry (TCR). The characteristics and overall survival of 71,334 lung cancer patients were analyzed according to the tumor, node, metastasis (TNM) 7th staging system. Univariate and multivariate analyses were performed to identify differences in 1-year, 3-year, and 5-year survival between different histopathologies of lung cancer. Results: The 1-year overall survival rate increased from 54.07% in 2010 to 66.14% in 2016. The 3-year overall survival rate increased from 26.57% in 2010 to 41.12% in 2016 in all patients. Among the histopathologies of lung cancer, 3-year overall survival of adenocarcinoma patients increased the most and largely contributed to the increased 3-year overall survival of all lung cancer patients. Conclusions: The introduction of target therapy has led to a tremendous increase in overall survival for lung adenocarcinoma patients. However, target therapy differs by histopathology. Choosing the right target therapy and determining the correct histopathology of lung cancer is a pivotal key in increasing the overall survival of patients. Together with immune therapy, the landscape of lung cancer treatments is changing.

show abstract

Section: Discussionsupporting

confidence: 89%

Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

Tsai

Huang

Hsieh

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…However, tumor location, an important factor affecting the prognosis of NSCLC, is not included in decisions regarding chemotherapy. Because tumors in different lobes are associated with different prognoses after surgery, radiotherapy, and immunotherapy [14][15][16][17], we examined the survival bene ts of perioperative chemotherapy according to the lobes affected to provide precise perioperative chemotherapy options that increase the survival bene t to patients.…”

Section: Introductionmentioning

confidence: 99%

Lobe-specific Analysis of Perioperative Chemotherapy for Non-small Cell Lung Cancer Patients

Lei

Mao

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives: Perioperative cisplatin-based chemotherapy decreases the risk of death over surgery alone and is a standard-of-care. Here, we examined perioperative chemotherapy indications for stage IB-III non-small cell lung cancer (NSCLC) patients according to lobe-specific analysis. Methods: Resectable NSCLC patients with stage IB–III who received perioperative chemotherapy with and without radiotherapy after lung resection were identified from the SEER database. Propensity score matching (PSM) analysis was performed to reduce the inherent bias of retrospective studies. The Kaplan–Meier method and log-rank tests were used to assess the differences in overall survival (OS). Results: The study enrolled 23,844 patients before PSM. The perioperative chemotherapy group had better OS than the non-perioperative chemotherapy group in stage IB–III NSCLC patients before and after PSM. However, subgroup analysis according to stage demonstrated that perioperative chemotherapy did not markedly benefit patients with stage IB. Furthermore, lobar subgroup analysis did not show survival advantages in primary tumors located in either the right middle lobe in stages II and III NSCLC or the right lower lobe in stage III NSCLC. Conclusions: Lobe-specific perioperative chemotherapy is recommended in NSCLC patients. For stage IB NSCLC, right middle lobe NSCLC from stage IB-III and right lower lobe NSCLC from stage III, perioperative chemotherapy might not confer survival benefits.

show abstract

“…Many reports were published on prognostic risk factors for LUAD: factors like age, sex, race, tumor-node-metastasis (TNM) stage, pathological grade, marital status, and therapeutic regimen are closely related to survival. The age of the patients is a confirmed risk factor for LUAD, and it always affects the type of therapeutic strategy ( 2 , 3 ). The majority of studies consider females are more likely to have a better prognosis, which may relate to the estrogen receptor beta (ER-β) pathway ( 2 , 4 - 7 ).…”

Section: Introductionmentioning

confidence: 99%

“…The age of the patients is a confirmed risk factor for LUAD, and it always affects the type of therapeutic strategy ( 2 , 3 ). The majority of studies consider females are more likely to have a better prognosis, which may relate to the estrogen receptor beta (ER-β) pathway ( 2 , 4 - 7 ). The race is also considered to be an independent prognostic factor for LUAD, with Asians, Pacific Islanders, and Hispanics experiencing better survival ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis

Wang¹,

Xu²,

Xu³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background The pathological differentiation of invasive adenocarcinoma (IAC) has been linked closely with epidemiological characteristics and clinical prognosis. However, the current models cannot accurately predict IAC outcomes and the role of pathological differentiation is confused. This study aimed to establish differentiation-specific nomograms to explore the effect of IAC pathological differentiation on overall survival (OS) and cancer-specific survival (CSS). Methods The data of eligible IAC patients between 1975 and 2019 were collected from the Surveillance, Epidemiology, and End Results (SEER) database, and randomly divided in a ratio of 7:3 into a training cohort and a validation cohort. The associations between pathological differentiation and other clinical characteristics were evaluated using chi-squared test. The OS and CSS analyses were performed using the Kaplan-Meier estimator, and the log-rank test was used for nonparametric group comparisons. Multivariate survival analysis was performed using a Cox proportional hazards regression model. The discrimination, calibration, and clinical performance of nomograms were assessed by area under receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA). Results A total of 4,418 IAC patients (1,001 high-differentiation, 1,866 moderate-differentiation, and 1,551 low-differentiation) were identified. Seven risk factors [age, sex, race, tumor-node-metastasis (TNM) stage, tumor size, marital status, and surgery] were screened to construct differentiation-specific nomograms. Subgroup analyses showed that disparate pathological differentiation played distinct roles in prognosis, especially in patients with older age, white race, and higher TNM stage. The AUC of nomograms for OS and CSS in the training cohort were 0.817 and 0.835, while in the validation cohort were 0.784 and 0.813. The calibration curves showed good conformity between the prediction of the nomograms and the actual observations. DCA results indicated that these nomogram models could be used as a supplement to the prediction of the TNM stage. Conclusions Pathological differentiation should be considered as an independent risk factor for OS and CSS of IAC. Differentiation-specific nomogram models with good discrimination and calibration capacity were developed in the study to predict the OS and CSS in 1-, 3- and 5-year, which could be used predict prognosis and select appropriate treatment options.

show abstract

Prognosis and Survival Analysis of 922,317 Lung Cancer Patients from the US Based on the Most Recent Data from the SEER Database (April 15, 2021)

Cited by 16 publications

References 40 publications

Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

Lobe-specific Analysis of Perioperative Chemotherapy for Non-small Cell Lung Cancer Patients

Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis

Contact Info

Product

Resources

About